Stomping out barriers for hRBC mouse models.

Erin A. Kimbrel,R. Lanza

DOI: https://doi.org/10.1182/blood-2011-09-381152

IF: 20.3

2011-11-24

Blood

Abstract:In this issue of Blood , Hu et al show that depletion of mouse macrophages enables the development and persistence of human red blood cells (hRBCs) in immunodeficient mouse models.[1][1] ![Figure][2] Suppression of mouse macrophages by clodronate liposomes (CLO-LIP) enables hRBC survival in

What problem does this paper attempt to address?

Coronary Plaque Characteristics in Hemodialysis-Dependent Patients As Assessed by Optical Coherence Tomography.

Chee Yang Chin,Mitsuaki Matsumura,Akiko Maehara,Wenbin Zhang,Cheolmin Tetsumin Lee,Myong Hwa Yamamoto,Lei Song,Yasir Parviz,Nisha B. Jhalani,Sumit Mohan,Lloyd E. Ratner,David J. Cohen,Ori Ben-Yehuda,Gregg W. Stone,Richard A. Shlofmitz,Tsunekazu Kakuta,Gary S. Mintz,Ziad A. Ali

DOI: https://doi.org/10.1016/j.amjcard.2017.01.022

IF: 3.133

2017-01-01

The American Journal of Cardiology

Abstract:Coronary arteries in patients with chronic kidney disease (CKD) have been shown to exhibit more extensive atherosclerosis and calcium. We aimed to assess characteristics of coronary plaque in hemodialysis (HD)-dependent patients using optical coherence tomography (OCT). This was a multicenter, retrospective study of 124 patients with stable angina who underwent OCT imaging. Sixty-two,HD-dependent patients who underwent pre-intervention OCT for coronary artery disease were compared 1:1 with a cohort of patients without CKD, matched for age, diabetes mellitus, gender, and culprit vessel. Baseline characteristics were comparable. Pre-intervention OCT imaging identified 62 paired culprit, 53 paired non-culprit, and 19 paired distal vessel lesions. Lesion length, minimum lumen area, and area stenosis were similar between groups. The HD-dependent group had greater mean calcium arcs in culprit (54.3 vs 26.4, p = 0.004) and non-culprit lesions (34.3 vs 24.5, p = 0.02) and greater maximum calcium arc in distal vessel segments (101.6 vs 0, p = 0.03). There were no differences in lipid arcs between groups. There was a higher prevalence of thin intimal calcium, defined as an arc of calcium >30 within intima <0.5 mm thick, in patients in the HD-dependent group (41.9% vs 4.8%, p <0.001). There was a higher prevalence of calcified nodules in the HD-dependent group (24.2% vs 9.7%, p = 0.049) but no differences in medial calcification or thin-cap fibroatheroma. In conclusion, in this OCT study, HD-dependent patients, compared with matched patients without CKD, had more extensively distributed coronary calcium and uniquely, a higher prevalence of non-atherosclerotic thin intimal calcium. This thin intimal calcium may cause an overestimation of calcium burden by intravascular ultrasound and may contribute to the lack of correlation between increased coronary artery calcification scores with long-term outcomes in patients with CKD. (C) 2017 Elsevier Inc. All rights reserved.
Predicting Cardiovascular Mortality in Chronic Kidney Disease (CKD) Patients.

Wenhui Sun,Dahai Liu,Ping Gong,Xiaoyu Shi,Yong Wang,Ping Wang,Weihua Gong

DOI: https://doi.org/10.12659/aot.891207

2014-01-01

Annals of Transplantation

Abstract:Cardiovascular mortality in chronic kidney disease (CKD) patients is a critical clinical challenge due to poor clinical outcome and increasing prevalence. Nephrologists and transplant specialists need suitable biomarkers to predict the occurrence of cardiovascular events and/or mortality in practice. At the technical level, development of a non-invasive repetitive sampling procedure is required to develop applicable biomarkers, offering a platform for clinicians to dynamically monitor the alteration of patient condition. Apart from specificity and sensitivity, the ideal biomarkers should be independent of various confounders such as sex, sex, age, kidney function, diabetes, and blood pressure. This article reviews recent studies on the identified potential biomarkers to analyze their predictive value and significance. The present study revealed that the identified potential biomarkers are involved in magnesium and phosphate metabolism, hormone dysregulation, pro-inflammatory process, and cardiovascular pathogenesis. Combined use of those biomarkers might allow early identification of subclinical cardiovascular system organ damage, effectively predict cardiovascular mortality, and significantly deepen our mechanistic understanding of the occurrence of cardiovascular events and mortality, which will help to develop preventive measures.
The Effect of Chronic Kidney Disease on the Long-Term Prognosis of Patients with Left Main Coronary Artery Disease after Revascularization

X P Yu,W J Wang,C Y Wu,Y Li,H Li,Y Zeng

DOI: https://doi.org/10.3760/cma.j.cn112137-20210617-01374

2021-01-01

Abstract:Objective: To analyze the effect of chronic kidney disease (CKD) on the long-term prognosis of patients with left main coronary artery disease after revascularization. Methods: A total of 1 040 patients with lesions in unprotected left main coronary artery who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) between January 2003 and July 2009 in Beijing An Zhen Hospital were enrolled (CKD group, n=240; non CKD group, n=800). The mean ages of CKD group and non CKD group were (68.9±6.5) and (61.1±9.7) years old, respectively. Patients were followed up through interviewing in clinic visit or calling by telephone. The primary endpoints of the study included death, myocardial infarction (MI) and stroke. Cox regression was used to analyze the associated factors on patients' long-term prognosis. Results: The median follow-up for included 1 040 patients was 6.1 years (first quartile Q1, 5.1 years; Q3, 8.0 years). The total occurrence of death, MI and stroke in the CKD group (48.9%, n=96) was significantly higher than that in the non CKD group (30.7%, n=136) (P<0.001). In the CKD group, the total occurrence of the death, MI and stroke was 51.2% in patients with PCI (n=46) compared to that of 47.2% in patients with CABG (n=50). In the non CKD group, the total occurrence of death, MI and stroke was 17.7% and 36.7% in patients with PCI (n=45) and CABG (n=91), respectively. Cox proportional hazards regression model analysis showed that after adjusted for confounding factors, the risk of all-cause death/MI/stroke [HR (95%CI): 1.97 (1.49-2.62)], all-cause death [2.67 (1.89-3.78)], cardiac death [3.46 (2.25-5.33)] and MI [2.31 (1.41-3.80)] increased in patients with CKD after revascularization. Conclusions: CKD significantly increases the occurrence of composite of death/MI/stroke, all-cause mortality, cardiac death and MI in patients with left main coronary artery disease after revascularization. There was no significant difference in the occurrence of the composite of death, MI and stroke between patients with PCI and those with CABG, regardless of in CKD group or non CKD group.
Synthesis and binding analysis of unique AG2 pentasaccharide to human Siglec-2 using NMR techniques.

S. Hanashima,Ken-Ichi Sato,Y. Naito,H. Takematsu,Y. Kozutsumi,Yukishige Ito,Y. Yamaguchi

DOI: https://doi.org/10.1016/j.bmc.2010.03.062

IF: 3.461

2010-06-01

Bioorganic & Medicinal Chemistry

Abstract:
Coronary artery calcification in patients with advanced chronic kidney disease

DOI: https://doi.org/10.1186/s12872-022-02879-0

IF: 2.174

2022-10-30

BMC Cardiovascular Disorders

Abstract:Cardiovascular disease (CVD) is associated with higher morbidity and mortality rates in patients with chronic kidney disease (CKD). Studies have shown that vascular calcification is a major predictor of CVD. Vascular calcification in the CKD population is associated with various risk factors, and changes in bone and mineral metabolism have been linked to an increased risk of atherosclerosis. Therefore, we aimed to investigate the correlation between vascular calcification and bone metabolism, which is necessary to improve the survival and prognosis of patients with CKD.

cardiac & cardiovascular systems
Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches

Philip Düsing,Andreas Zietzer,Philip Roger Goody,Mohammed Rabiul Hosen,Christian Kurts,Georg Nickenig,Felix Jansen

DOI: https://doi.org/10.1007/s00109-021-02037-7

2021-01-22

Journal of Molecular Medicine

Abstract:Abstract Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney disease (CKD). Both conditions are rising in incidence as well as prevalence, creating poor outcomes for patients and high healthcare costs. Recent data suggests CKD to be an independent risk factor for CVD. Accumulation of uremic toxins, chronic inflammation, and oxidative stress have been identified to act as CKD-specific alterations that increase cardiovascular risk. The association between CKD and cardiovascular mortality is markedly influenced through vascular alterations, in particular atherosclerosis and vascular calcification (VC). While numerous risk factors promote atherosclerosis by inducing endothelial dysfunction and its progress to vascular structural damage, CKD affects the medial layer of blood vessels primarily through VC. Ongoing research has identified VC to be a multifactorial, cell-mediated process in which numerous abnormalities like mineral dysregulation and especially hyperphosphatemia induce a phenotype switch of vascular smooth muscle cells to osteoblast-like cells. A combination of pro-calcifying stimuli and an impairment of inhibiting mechanisms like fetuin A and vitamin K-dependent proteins like matrix Gla protein and Gla-rich protein leads to mineralization of the extracellular matrix. In view of recent studies, intercellular communication pathways via extracellular vesicles and microRNAs represent key mechanisms in VC and thereby a promising field to a deeper understanding of the involved pathomechanisms. In this review, we provide an overview about pathophysiological mechanisms connecting CKD and CVD. Special emphasis is laid on vascular alterations and more recently discovered molecular pathways which present possible new therapeutic targets.
Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification

Zhuoming Dai,Xiangyu Zhang

DOI: https://doi.org/10.3390/jcdd10050207

2023-05-10

Journal of Cardiovascular Development and Disease

Abstract:The global prevalence of chronic kidney disease (CKD) has increased in recent years. Adverse cardiovascular events have become the main cause of life-threatening events in patients with CKD, and vascular calcification is a risk factor for cardiovascular disease. Vascular calcification, especially coronary artery calcification, is more prevalent, severe, rapidly progressive, and harmful in patients with CKD. Some features and risk factors are unique to vascular calcification in patients with CKD; the formation of vascular calcification is not only influenced by the phenotypic transformation of vascular smooth muscle cells, but also by electrolyte and endocrine dysfunction, uremic toxin accumulation, and other novel factors. The study on the mechanism of vascular calcification in patients with renal insufficiency can provide a basis and new target for the prevention and treatment of this disease. This review aims to illustrate the impact of CKD on vascular calcification and to discuss the recent research data on the pathogenesis and factors involved in vascular calcification, mainly focusing on coronary artery calcification, in patients with CKD.

cardiac & cardiovascular systems
Current Understanding of Cardiovascular Calcification in Patients with Chronic Kidney Disease

Sijie Chen,Rining Tang,Bicheng Liu

DOI: https://doi.org/10.3390/ijms251810225

IF: 5.6

2024-09-24

International Journal of Molecular Sciences

Abstract:The burden of chronic kidney disease (CKD) is increasing, posing a serious threat to human health. Cardiovascular calcification (CVC) is one of the most common manifestations of CKD, which significantly influences the morbidity and mortality of patients. The manifestation of CVC is an unusual accumulation of mineral substances containing calcium and phosphate. The main component is hydroxyapatite. Many cells are involved in this process, such as smooth muscle cells (SMCs) and endothelial cells. CVC is an osteogenic process initiated by complex mechanisms such as metabolic disorders of calcium and phosphorus minerals, inflammation, extracellular vesicles, autophagy, and micro-RNAs with a variety of signaling pathways like Notch, STAT, and JAK. Although drug therapy and dialysis technology continue to advance, the survival time and quality of life of CVC patients still face challenges. Therefore, early diagnosis and prevention of CKD-related CVC, reducing its mortality rate, and improving patients' quality of life have become urgent issues in the field of public health. In this review, we try to summarize the state-of-the-art understanding of the progression of CVC and hope that it will help in the prevention and treatment of CVC in CKD.

biochemistry & molecular biology,chemistry, multidisciplinary
Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health

Danish Saeed,Taufiqa Reza,Muhammad Waqas Shahzad,Alishba Karim Mandokhail,Danyal Bakht,Farwa Haider Qizilbash,Elizabeth O Silloca-Cabana,Afif Ramadhan,Syed Faqeer Hussain Bokhari

DOI: https://doi.org/10.7759/cureus.51362

2023-12-30

Cureus

Abstract:Chronic Kidney Disease (CKD) has emerged as a global healthcare challenge affecting a significant portion of the world's population. This comprehensive narrative review delves into the intricate relationship between CKD and cardiovascular disease (CVD). CKD is characterized by kidney damage persisting for at least three months, often with or without a decline in glomerular filtration rate (GFR). It is closely linked with CVD, as individuals with CKD face a high risk of cardiovascular events, making cardiovascular-associated mortality a significant concern in advanced CKD stages. The review emphasizes the importance of precise risk assessment using biomarkers, advanced imaging, and tailored medication strategies to mitigate cardiovascular risks in CKD patients. Lifestyle modifications, early intervention, and patient-centered care are crucial in managing both conditions. Challenges in awareness and recognition of CKD and the need for comprehensive interdisciplinary care are highlighted. Recent advances in research offer promising therapies, such as SGLT2 inhibitors, MRAs, GLP-1R agonists, and selective endothelin receptor antagonists. Stem cell-based therapies, gene editing, and regenerative approaches are under investigation. Patient-physician "risk discussions" and tailored risk assessments are essential for improving patient outcomes. In conclusion, the review underscores the complexity of the interconnected CKD and cardiovascular health domains. Ongoing research, innovative therapies, and personalized healthcare will be instrumental in addressing the challenges, reducing the disease burden, and enhancing well-being for individuals facing CKD and cardiovascular issues. Recognizing the intricate connections between these conditions is imperative for healthcare providers, policymakers, and researchers as they seek to improve the quality of care and outcomes for affected individuals.
Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease

Joshua D. Hutcheson,Claudia Goettsch

DOI: https://doi.org/10.1161/CIRCRESAHA.123.321760

IF: 23.213

2023-04-15

Circulation Research

Abstract:Circulation Research, Volume 132, Issue 8, Page 993-1012, April 14, 2023. Patients with chronic kidney disease (CKD) exhibit tremendously elevated risk for cardiovascular disease, particularly ischemic heart disease, due to premature vascular and cardiac aging and accelerated ectopic calcification. The presence of cardiovascular calcification associates with increased risk in patients with CKD. Disturbed mineral homeostasis and diverse comorbidities in these patients drive increased systemic cardiovascular calcification in different manifestations with diverse clinical consequences, like plaque instability, vessel stiffening, and aortic stenosis. This review outlines the heterogeneity in calcification patterning, including mineral type and location and potential implications on clinical outcomes. The advent of therapeutics currently in clinical trials may reduce CKD-associated morbidity. Development of therapeutics for cardiovascular calcification begins with the premise that less mineral is better. While restoring diseased tissues to a noncalcified homeostasis remains the ultimate goal, in some cases, calcific mineral may play a protective role, such as in atherosclerotic plaques. Therefore, developing treatments for ectopic calcification may require a nuanced approach that considers individual patient risk factors. Here, we discuss the most common cardiac and vascular calcification pathologies observed in CKD, how mineral in these tissues affects function, and the potential outcomes and considerations for therapeutic strategies that seek to disrupt the nucleation and growth of mineral. Finally, we discuss future patient-specific considerations for treating cardiac and vascular calcification in patients with CKD—a population in need of anticalcification therapies.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts

Carla Viegas,Nuna Araújo,Catarina Marreiros,Dina Simes

DOI: https://doi.org/10.18632/aging.102046

2019-06-26

Aging

Abstract:Chronic kidney disease (CKD) is one of the most powerful predictors of premature cardiovascular disease (CVD), with heightened susceptibility to vascular intimal and medial calcification associated with a high cardiovascular mortality. Abnormal mineral metabolism of calcium (Ca) and phosphate (P) and underlying (dys)regulated hormonal control in CKD-mineral and bone disorder (MBD) is often accompanied by bone loss and increased vascular calcification (VC). While VC is known to be a multifactorial process and a major risk factor for CVD, the view of primary triggers and molecular mechanisms complexity has been shifting with novel scientific knowledge over the last years. In this review we highlight the importance of calcium-phosphate (CaP) mineral crystals in VC with an integrated view over the complexity of CKD, while discuss past and recent literature aiming to highlight novel horizons on this major health burden. Exacerbated VC in CKD patients might result from several interconnected mechanisms involving abnormal mineral metabolism, dysregulation of endogenous calcification inhibitors and inflammatory pathways, which function in a feedback loop driving disease progression and cardiovascular outcomes. We propose that novel approaches targeting simultaneously VC and inflammation might represent valuable new prognostic tools and targets for therapeutics and management of cardiovascular risk in the CKD population.
Role of Chronic Kidney Disease (CKD)–Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD

T. Nakano,S. Yamada

DOI: https://doi.org/10.5551/jat.RV22006

2023-05-30

Journal of Atherosclerosis and Thrombosis

Abstract:Cardiovascular disease (CVD) is the leading cause of death in patients with chronic kidney disease (CKD). Multiple factors account for the increased incidence of cardiovascular morbidity and mortality in patients with CKD. Traditional risk factors for atherosclerosis and arteriosclerosis, including age, hypertension, dyslipidemia, diabetes mellitus, and smoking, are also risk factors for CKD. Non-traditional risk factors specific for CKD are also involved in CVD pathogenesis in patients with CKD. Recently, CKD–mineral and bone disorder (CKD–MBD) has emerged as a key player in CVD pathogenesis in the context of CKD. CKD–MBD manifests as hypocalcemia and hyperphosphatemia in the later stages of CKD; however, it initially develops much earlier in disease course. The initial step in CKD–MBD involves decreased phosphate excretion in the urine, followed by increased circulating concentrations of fibroblast growth factor 23 (FGF23) and parathyroid hormone (PTH), which increase urinary phosphate excretion. Simultaneously, the serum calcitriol concentration decreases as a result of FGF23 elevation. Importantly, FGF23 and PTH cause left ventricular hypertrophy, arrhythmia, and cardiovascular calcification. More recently, calciprotein particles, which are nanoparticles composed of calcium, phosphate, and fetuin-A, among other components, have been reported to cause inflammation, cardiovascular calcification, and other clinically relevant outcomes. CKD–MBD has become one of the critical therapeutic targets for the prevention of cardiovascular events and is another link between cardiology and nephrology. In this review, we describe the role of CKD–MBD in the pathogenesis of cardiovascular disorders and present the current treatment strategies for CKD–MBD.

Environmental Science,Medicine
Adsorption and catalytic properties of the inner nanospace of a gigantic ring-shaped polyoxometalate cluster.

S. Noro,R. Tsunashima,Y. Kamiya,K. Uemura,H. Kita,L. Cronin,T. Akutagawa,Takayoshi Nakamura

DOI: https://doi.org/10.1002/anie.200903142

2009-11-02

Angewandte Chemie

Abstract:are of great interestbecause of their unique properties such as adsorption,separation, exchange, and catalysis, which are all associatedwith the presence of a functional nanospace. In this respect,polyoxometalate clusters, which are nanosized metal-oxidemacroanions built from molecular precursors with a range ofunique redox and acidic properties, are ideally suited for thedevelopment of functional nanospaces but have not yet beenthus explored.
Demonstration of an SOA Efficient 32×32 Optical Switch for Radio Over Fiber Distribution Systems

M. Crisp,E. T. Aw,A. Wonfor,R. Penty,I. White

DOI: https://doi.org/10.1109/OFC.2008.4528511

2008-02-24

Abstract:A 32x32 optical RoF switch is demonstrated. A 13 dB input dynamic range with acceptable EVM and, using open loop control, an input dynamic range of 10 dB with 1 dB variation in output RF power is achieved.
Correlation between coronary calcification and cardiac structure in non-dialysis patients with chronic kidney disease

Siyi Rao,Mengjie Weng,Ruoshan Lian,Yongjie Zhuo,Jiaqun Lin,Danyu You,Jiong Cui,Yi Chen,Jianxin Wan

DOI: https://doi.org/10.1002/ehf2.15057

2024-09-06

Abstract:Aims: We aim to explore the correlation between coronary artery calcification (CAC) score (CACS) and cardiac structure and function in chronic kidney disease (CKD) patients, create a clinical prediction model for severe CAC associated with cardiac ultrasound indexes. Methods and results: The study included 178 non-dialysis CKD patients who underwent CACS testing and collected general information, serological indices, cardiac ultrasound findings and follow-up on renal function, heart failure (HF) manifestations and re-hospitalization. The mean age of participants in the study cohort was 67.4 years; 59% were male, and 66.9% of patients had varying degrees of comorbid CAC. CKD patients with CACS > 100 were older, predominantly male and had a higher proportion of smoking, diabetes and hypertension (P < 0.05) compared with those with CACS = 0 and 0 < CACS ≤ 100, and had higher brain natriuretic peptide, serum magnesium and fibrinogen levels were also higher (P < 0.05). CACS was positively correlated with left atrial inner diameter (LAD), left ventricular end-diastolic inner diameter (LVDd), left ventricular volume at diastole (LVVd), output per beat (SV) and mitral orifice early diastolic blood flow velocity/early mitral annular diastolic myocardial motion velocity (E/e) (P < 0.05). We tested the associations between varying degrees of CAC and HF and heart valve calcification using multivariable-adjusted regression models. The risk of HF in patients with severe CAC was about 1.95 times higher than that in patients without coronary calcification, and the risk of heart valve calcification was 2.46 times higher than that in patients without coronary calcification. Heart valve calcification and HF diagnosis, LAD and LVDd are essential in predicting severe CAC. During a mean follow-up time of 18.26 ± 10.17 months, 65 (36.52%) patients had a composite renal endpoint event, of which 36 (20.22%) were admitted to renal replacement therapy. Patients with severe CAC had a higher risk of progression of renal function, re-admission due to cardiovascular and renal events and more pronounced symptoms of HF (P < 0.05). Conclusions: There is a correlation between CACS and cardiac structure and function in non-dialysis CKD patients, which may mainly involve abnormalities in left ventricular structure and cardiac diastolic function. CAC may affect renal prognosis and quality of survival in CKD patients. Based on clinical information, HF, valvular calcification status and indicators related to left ventricular hypertrophy can identify people at risk for severe CAC.
Diagnosis of cardiovascular disease in patients with chronic kidney disease

Carmine Zoccali,Patrick B. Mark,Pantelis Sarafidis,Rajiv Agarwal,Marcin Adamczak,Rodrigo Bueno de Oliveira,Ziad A. Massy,Peter Kotanko,Charles J. Ferro,Christoph Wanner,Michel Burnier,Raymond Vanholder,Francesca Mallamaci,Andrzej Wiecek

DOI: https://doi.org/10.1038/s41581-023-00747-4

IF: 42.439

2023-08-24

Nature Reviews Nephrology

Abstract:Patients with chronic kidney disease (CKD) are at high risk of cardiovascular disease (CVD) and cardiovascular death. Identifying and monitoring cardiovascular complications and hypertension is important for managing patients with CKD or kidney failure and transplant recipients. Biomarkers of myocardial ischaemia, such as troponins and electrocardiography (ECG), have limited utility for diagnosing cardiac ischaemia in patients with advanced CKD. Dobutamine stress echocardiography, myocardial perfusion scintigraphy and dipyridamole stress testing can be used to detect coronary disease in these patients. Left ventricular hypertrophy and left ventricular dysfunction can be detected and monitored using various techniques with differing complexity and cost, including ECG, echocardiography, nuclear magnetic resonance, CT and myocardial scintigraphy. Atrial fibrillation and other major arrhythmias are common in all stages of CKD, and ambulatory heart rhythm monitoring enables precise time profiling of these disorders. Screening for cerebrovascular disease is only indicated in asymptomatic patients with autosomal dominant polycystic kidney disease. Standardized blood pressure is recommended for hypertension diagnosis and treatment monitoring and can be complemented by ambulatory blood pressure monitoring. Judicious use of these diagnostic techniques may assist clinicians in detecting the whole range of cardiovascular alterations in patients with CKD and enable timely treatment of CVD in this high-risk population.

urology & nephrology
Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease

Cuicui Xu,George Tsihlis,Katrina Chau,Katie Trinh,Natasha M. Rogers,Sohel M. Julovi

DOI: https://doi.org/10.3390/ijms25052658

IF: 5.6

2024-02-25

International Journal of Molecular Sciences

Abstract:Chronic kidney disease (CKD) affects > 10% of the global adult population and significantly increases the risk of cardiovascular disease (CVD), which remains the leading cause of death in this population. The development and progression of CVD—compared to the general population—is premature and accelerated, manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. CKD and CV disease combine to cause multimorbid cardiorenal syndrome (CRS) due to contributions from shared risk factors, including systolic hypertension, diabetes mellitus, obesity, and dyslipidemia. Additional neurohormonal activation, innate immunity, and inflammation contribute to progressive cardiac and renal deterioration, reflecting the strong bidirectional interaction between these organ systems. A shared molecular pathophysiology—including inflammation, oxidative stress, senescence, and hemodynamic fluctuations characterise all types of CRS. This review highlights the evolving paradigm and recent advances in our understanding of the molecular biology of CRS, outlining the potential for disease-specific therapies and biomarker disease detection.

biochemistry & molecular biology,chemistry, multidisciplinary
Atherosclerosis and Vascular Calcification in Chronic Renal Failure

V. Campean,D. Neureiter,I. Varga,F. Runk,A. Reiman,C. Garlichs,S. Achenbach,B. Nonnast-Daniel,K. Amann

DOI: https://doi.org/10.1159/000090182

2005-01-01

Abstract:Cardiovascular complications are a major clinical problem in patients with chronic kidney disease and end-stage renal failure; cardiac death accounts for approximately 40-50% of all deaths in these patients. Death from cardiovascular causes is up to 20 times more common in uremic patients than in the general population with the risk being even higher than in patients with diabetes mellitus. A high rate of myocardial infarction and excessive cardiac mortality have repeatedly been documented in patients with kidney disease and renal failure. Not only is the prevalence of myocardial infarction high, but also the case fatality rate is significantly higher in uremic patients with and without diabetes, respectively, compared to nonuremic patients. This is of particular interest since the prevalence of coronary atheroma in uremic patients was shown to be approximately 30% by autopsy and coronary angiography studies. Thus, coronary factors, i.e. atherosclerosis, and non-coronary factors may play an important role in the genesis of cardiac complications in the renal patient. In addition, renal failure recently has also be identified as a predictor of mortality in different stages of peripheral vascular disease. In particular, marked differences in the pathogenesis, morphology and course of atherosclerosis and arteriosclerosis under the conditions of renal failure have been documented. Among others increased plaque formation and particularly higher proportion and intensity of vascular calcification have been found in clinical and autopsy studies. In addition to the so-called classical or traditional risk factors, an important role for nonclassical risk factors such as microinflammation, hyperphosphatemia and oxidative stress has been documented in patients with renal failure and is discussed in detail.

peripheral vascular disease,urology & nephrology,physiology
Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescence

Julia Carracedo,Matilde Alique,Carmen Vida,Guillermo Bodega,Noemí Ceprián,Enrique Morales,Manuel Praga,Patricia de Sequera,Rafael Ramírez

DOI: https://doi.org/10.3389/fcell.2020.00185

IF: 5.5

2020-03-20

Frontiers in Cell and Developmental Biology

Abstract:Cardiovascular diseases (CVDs), especially those involving a systemic inflammatory process such as atherosclerosis, remain the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is a systemic condition affecting approximately 10% of the general population. The prevalence of CKD has increased over the past decades because of the aging of the population worldwide. Indeed, CVDs in patients with CKD constitute a premature form of CVD observed in the general population. Multiple studies indicate that patients with renal disease undergo accelerated aging, which precipitates the appearance of pathologies, including CVDs, usually associated with advanced age. In this review, we discuss several aspects that characterize CKD-associated CVDs, such as etiopathogenic elements that CKD patients share with the general population, changes in the cellular balance of reactive oxygen species (ROS), and the associated process of cellular senescence. Uremia-associated aging is linked with numerous changes at the cellular and molecular level. These changes are similar to those observed in the normal process of physiologic aging. We also discuss new perspectives in the study of CKD-associated CVDs and epigenetic alterations in intercellular signaling, mediated by microRNAs and/or extracellular vesicles (EVs), which promote vascular damage and subsequent development of CVD. Understanding the processes and factors involved in accelerated senescence and other abnormal intercellular signaling will identify new therapeutic targets and lead to improved methods of diagnosis and monitoring for patients with CKD-associated CVDs.

cell biology,developmental biology

Stomping out barriers for hRBC mouse models.

Coronary Plaque Characteristics in Hemodialysis-Dependent Patients As Assessed by Optical Coherence Tomography.

Predicting Cardiovascular Mortality in Chronic Kidney Disease (CKD) Patients.

The Effect of Chronic Kidney Disease on the Long-Term Prognosis of Patients with Left Main Coronary Artery Disease after Revascularization

Synthesis and binding analysis of unique AG2 pentasaccharide to human Siglec-2 using NMR techniques.

Coronary artery calcification in patients with advanced chronic kidney disease

Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches

Pathophysiology and Clinical Impacts of Chronic Kidney Disease on Coronary Artery Calcification

Current Understanding of Cardiovascular Calcification in Patients with Chronic Kidney Disease

Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health

Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease

The interplay between mineral metabolism, vascular calcification and inflammation in Chronic Kidney Disease (CKD): challenging old concepts with new facts

Role of Chronic Kidney Disease (CKD)–Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD

Adsorption and catalytic properties of the inner nanospace of a gigantic ring-shaped polyoxometalate cluster.

Demonstration of an SOA Efficient 32×32 Optical Switch for Radio Over Fiber Distribution Systems

Correlation between coronary calcification and cardiac structure in non-dialysis patients with chronic kidney disease

Diagnosis of cardiovascular disease in patients with chronic kidney disease

Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease

Atherosclerosis and Vascular Calcification in Chronic Renal Failure

Mechanisms of Cardiovascular Disorders in Patients With Chronic Kidney Disease: A Process Related to Accelerated Senescence